Lisata Therapeutics Inc (LSTA)

[whirlybird]

Cat out of the Bag: Positive results highly likely.

NBS is conducting a PreSERVE P2 trial for acute myocardial infarction (AMI) using its proprietary stem cells AMR-001 (CD 34) administered via coronary arteries. A fourth data monitoring review recommended on March 17, 2014 that the trial continue. At this time BAX is also conducting a RENEW study for Chronic Myocardial Ischemia (CMI) using stem cells purchased from the NBS subsidiary Progenitor Cell Therapy (PCT) that are injected into the heart. Results for both studies are expected coincidentally around July 2014.

Optimism is based on a CADUCEUS (http://www.ncbi.nlm.nih.gov/pubmed/22336189) study using intracoronary cardiosphere derived stem cells and more convincingly a host of European studies using PCT stem cells (http://eurheartj.oxfordjournals.org/content/29/15/1807.full.pdf). Cardio3 BioSciences is partnering with the Mayo Clinic studies using NBS PCT stem cells injected into the heart for heart failure following MIs (http://www.upi.com/Health_News/2014/01/17/Mayo-Clinic-to-test-adult-stem-cells-to-treat-heart-failure/UPI-46731390019847/). Another Mayo researcher, Dr. Terzic, said regarding the use of NBS PCT cells, "It's critical that this new process of cardiopoiesis was achieved in 100 percent of cases, with a very good safety profile." (http://www.mayo.edu/research/discoverys-edge/regenerating-heart-tissue-stem-cell-therapy)

Although 100% cardiopoiesis does not necessarily correlate with 100% improvement in left ventricular function, Dr. Turiks’s assertion seems to let the cat out of the bag that the RENEW results will be positive.